IRF5-CPP5
Based on 1 Customer Validation
IRF5-CPP5 is a cytosolic peptide that selectively targeting human IRF5 wirh a Kd of 0.53 μM. IRF5-CPP5 disrupts IRF5 homodimerization and inhibits its nuclear translocation without altering IRF5 phosphorylation levels. IRF5-CPP5 inhibits proinflammatory cytokine (IL-6, IL-1β, TNF-α) production. IRF5-CPP5 can be used for the research of systemic lupus erythematosus.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.23%
- CAS No.: 1601299-92-6
- Formule: C160H245N37O36S
- Masse moléculaire:3294.95
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
|
IL-6 |
IL-1β |
IRF5-CPP5 binds to recombinant monomeric IRF5 (222 to 425) with a submicromolar Kd of 0.53 μM[1].
IRF5-CPP5 inhibits homodimerization of recombinant full-length IRF5 S430D and WT variants with IC50 values of 15.3 and 15.4 μM[1].
IRF5-CPP5 (1-10 μM; 1 h) dose-dependently inhibits R848 (HY-13740 -induced endogenous IRF5 homodimerization in THP-1 human monocytic cells[1].
IRF5-CPP5 (5 μM; 30-60 min) penetrates and colocalizes with endogenous IRF5 in human primary CD19+ B cells, CD14+ monocytes, and BDCA2+ CD123+ pDCs[1].
IRF5-CPP5 (0.62-50 μM; 30 min) concentration-dependently inhibits R848-induced IL12p40 production in human primary PBMCs[1].
IRF5-CPP5 (0.62-16.07 μM) concentration-dependently inhibits R848-induced IRF5 nuclear translocation in human primary CD14+ monocytes and CD19+ B cells[1].
IRF5-CPP5 (3.5-15 μM; 1 h) significantly inhibits LPS(HY-D1056) - and R848-induced proinflammatory cytokine (IL-6, IL-1β, TNF-α) production and transcript expression in human primary MDMs[1].
IRF5-CPP5 (0.62-50 μM) concentration-dependently inhibits CpGA-induced IFNα production in human primary BDCA2+ CD123+ pDCs[1].
IRF5-CPP5 (0.62-16.07 μM; 30 min) concentration-dependently inhibits SLE serum-induced IRF5 and phosphorylated IRF5 (pSer462) nuclear translocation in human primary CD14+ monocytes, CD19+ B cells, and BDCA2+ CD123+ pDCs, without altering total pIRF5 levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:THP-1 human monocytic cells
-
Concentration:1, 10 μM
-
Incubation Time:1 h
-
Result:Reduced (IRF5)2 levels.
Chemical Information
-
CAS No. 1601299-92-6
-
Appearance Solid
-
Masse moléculaire 3294.95
-
Formule C160H245N37O36S
-
Color White to off-white
-
Sequence
Met-Ala-Asn-Leu-Gly-Tyr-Trp-Leu-Leu-Ala-Leu-Phe-Val-Thr-Tyr-Trp-Thr-Asp-Leu-Gly-Leu-Val-Lys-Lys-Arg-Pro-Lys-Pro
-
Sequence Shortening
MANLGYWLLALFVTYWTDLGLVKKRPKP
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvant et solubilité
DMSO : 50 mg/mL (15.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.3035 mL | 1.5175 mL | 3.0349 mL | 7.5874 mL |
| 5 mM | 0.0607 mL | 0.3035 mL | 0.6070 mL | 1.5175 mL | |
| 10 mM | 0.0303 mL | 0.1517 mL | 0.3035 mL | 0.7587 mL | |
| 15 mM | 0.0202 mL | 0.1012 mL | 0.2023 mL | 0.5058 mL |
IRF5-CPP5 Related Classifications
HY-P11072 Related Classifications
Powered by Bioz